SavedAdd your journal

Journals / Anatolian Current Medical Journal / 2026 / Volume: 8 Issue: 5

Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center

Muhammet Cengiz(erciyes)0000-0002-2028-9687
Ayşe Nuransoy Cengiz(ERCIYES UNIVERSITY)0000-0001-9133-8602
Oktay Bozkurt(ERCIYES UNIVERSITY)0000-0003-3551-5234
Mevlüde İnanç(ERCIYES UNIVERSITY)0000-0002-3737-3420
Metin Özkan(ERCIYES UNIVERSITY)0000-0003-0359-0504
Pages
—
Publication Date
2026-09-11
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Overall survival was superior in the cabozantinib group, with a median of 21 months in sunitinib versus 47 months in cabozantinib group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Fifty percent of patients with metastatic renal cell carcinoma (RCC) die within the first year.
📊
Key Findings & Data:Methods: A total of 108 patients with metastatic RCC were stratified according to whether they received sunitinib or cabozantinib.
💡
Conclusion & Impact:Results: Overall survival was superior in the cabozantinib group, with a median of 21 months in sunitinib versus 47 months in cabozantinib group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Metastatic renal cell cancer · cabozantinib · sunitinib

Abstract

Aims: Fifty percent of patients with metastatic renal cell carcinoma (RCC) die within the first year. Therefore, survival in the first-line setting is of paramount importance. Cabozantinib has been introduced for use in the first-line setting. We plan to conduct a study on its contribution to survival in Turkiye's population. Methods: A total of 108 patients with metastatic RCC were stratified according to whether they received sunitinib or cabozantinib. The two groups were similar in terms of their demographic characteristics. Survival outcomes and prognostic factors influencing survival were analyzed. Results: Overall survival was superior in the cabozantinib group, with a median of 21 months in sunitinib versus 47 months in cabozantinib group. International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score and cabozantinib treatment were identified as independent prognostic factors by multivariant analysis. Conclusion: Tyrosine kinase inhibitor therapies continue to play a significant role in the treatment of metastatic RCC. In countries where combination therapy with immune checkpoint inhibitors is not available, cabozantinib is a good option and may improve survival rates.

🔖

Cite This Article

Cengiz, M., Cengiz, A. N., Bozkurt, O., İnanç, M., Özkan, M. (2026). Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center. Anatolian Current Medical Journal, Volume: 8 Issue: 5. https://doi.org/10.38053/acmj.1976605

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and prevention of renal cell carcinoma. Cancers (Basel). 2022;14(16):4059. doi:10.3390/cancers14164059
  2. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87. doi:10.14740/wjon1279
  3. Kanwal R. Metastasis in renal cell carcinoma: biology and treatment. Adv Cancer Biol Metastasis. 2023;7:100094. doi:10.1016/j.adcanc.2023.100094
  4. Roskoski R Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res. 2017; 120:116-132. doi:10.1016/j.phrs.2017.03.010
  5. Abdelaziz A, Vaishampayan U. Cabozantinib for renal cell carcinoma: current and future paradigms. Curr Treat Options Oncol. 2017;18(3):18. doi:10.1007/s11864-017-0444-6
  6. Chen RC, Choueiri TK, Feuilly M, et al. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). Cancer. 2020; 126(24):5311-5318. doi:10.1002/cncr.33169
  7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. doi:10.1056/NEJMoa065044
  8. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015;21(5):1071-1077. doi:10.1158/1078-0432.CCR-14-1993
  9. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115-125. doi:10.1016/j.ejca.2018.02.012
  10. Vermassen T, De Meulenaere A, Van de Walle M, Rottey S. Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma. Acta Clin Belg. 2017;72(1):12-18. doi:10.1080/17843286.2016.1193269
  11. Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692-706. doi:10.1016/j.annonc.2024.05.537
  12. Şahin G, Tüzün EK, Güzel HG, et al. Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: a multicenter study by the Turkish Oncology Group. Int J Cancer. 2026;158(4):1067-1079. doi:10.1002/ijc.70165
  13. Lee D, Ahmad Z, Larkin JMG, Bahl A, Melendez-Torres GJ. Structured expert elicitation to inform long-term survival extrapolations in advanced renal cell carcinoma. Appl Health Econ Health Policy. 2025;23(6):1073-1083. doi:10.1007/s40258-025-01000-8
  14. McGrane J, Frazer R, Challapalli A, et al. Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the UK Renal Oncology Collaborative (UK ROC): is it time to look favourably on first-line immunotherapy containing combinations in all IMDC groups? Cancer Med. 2024;13(12):e7327. doi:10.1002/cam4.7327